May 2003
Volume 44, Issue 13
ARVO Annual Meeting Abstract  |   May 2003
Safety and Tolerability of Epinastine HCl 0.05% Ophthalmic Solution in Healthy Adults
Author Affiliations & Notes
  • C. Michaelson
    Ophthalmic Research Assoc., North Andover, MA, United States
  • R. Bradford
    Allergan, Irvine, CA, United States
  • R. Schiffman
    Allergan, Irvine, CA, United States
  • J. Lue
    Allergan, Irvine, CA, United States
  • B. Kim
    Allergan, Irvine, CA, United States
  • S. Whitcup
    Allergan, Irvine, CA, United States
  • Footnotes
    Commercial Relationships  C. Michaelson, None; R. Bradford, Allergan E; R. Schiffman, Allergan E; J. Lue, Allergan E; B. Kim, Allergan E; S. Whitcup, Allergan E.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 3730. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C. Michaelson, R. Bradford, R. Schiffman, J. Lue, B. Kim, S. Whitcup; Safety and Tolerability of Epinastine HCl 0.05% Ophthalmic Solution in Healthy Adults . Invest. Ophthalmol. Vis. Sci. 2003;44(13):3730.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: This single-center, randomized, double-masked study evaluated the safety and tolerability of epinastine ophthalmic solution in healthy adults Methods: Subjects were randomly assigned to receive epinastine HCl 0.05% (n=120) or vehicle (n=60) administered 1 drop in both eyes for 6 weeks. Biomicroscopy before and after instillation and visual acuity examinations were conducted at 4 study visits on days 0 (baseline), 7, 21, and 42. Intraocular pressure (IOP) measurements and pre-instillation ophthalmoscopic examinations were conducted on days 0 and 42. Results: Mean age of participants was 41.0 years (range 18-77); 40.6% were male and 59.4% female. No clinically or statistically significant differences in frequencies of adverse events (AEs) overall or of any individual adverse event were observed between treatment groups. AEs were reported in 15.8% of epinastine subjects and 25% of vehicle subjects. Infection, primarily colds/URI, was the most frequent AE reported in 5.0% of epinastine subjects and 8.3% of vehicle subjects. There was a significantly lower frequency of ocular AEs in the epinastine group compared to the vehicle group, 1.7% vs. 11.7% respectively (P=0.007). No significant differences were observed between groups in pre-instillation biomicroscopy findings relative to baseline, or in comparisons of pre-instillation with post-instillation biomicroscopy findings. No significant between group differences in IOP, visual acuity, or ophthalmoscopy were observed. Conclusions: Epinastine 0.05% ophthalmic solution instilled BID for 6 weeks was safe and well-tolerated by healthy adults.

Keywords: clinical (human) or epidemiologic studies: tre • drug toxicity/drug effects • pharmacology 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.